Zeltia

Yondelis(R) sales increase by 70 percent

Fast Track status is granted to facilitate development and expedite the review of a drug for a serious or potentially fatal illness and to meet an unmet medical need.

Sylentis Completes Phase I Trial with SYL040012 to Treat Elevated Intraocular Pressure and Glaucoma

Yondelis(R) sales increased by 110% with respect to 1Q09

MADRID, February 24, 2011 - Zeltia Group's net revenues totalled 153.5 million euro in 2010, 24.4 percent more than in 2009 (123.4 million euro).

MORE..

MADRID, September 10, 2010 - Noscira, a Grupo Zeltia (ZEL.MC) subsidiary specialised in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S.

MORE..

MADRID, July 7, 2010 - Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

MORE..

Older News

MADRID, April 29, 2010 - Consolidated revenues for Zeltia (ZEL.MC) amounted to 32.9 million euro in 1Q10, up 49% with respect to 1Q09.

MORE..